ViCapsys

ViCapsys is a private, pre-revenue biotech leveraging a platform based on the cytokine CXCL12 to locally modulate immune and inflammatory responses. Its lead program aims to enable long-term survival of transplanted pancreatic islet cells to cure Type 1 Diabetes, with supporting data from non-human primate studies. The company is also developing non-cellular applications for diabetic foot ulcers and abdominal adhesions, building on intellectual property licensed from Massachusetts General Hospital.

Localized immunomodulation platform based on optimized formulations of the pleiotropic cytokine CXCL12. The platform leverages chemotaxis and fugetaxis (cell repulsion) to create protective microenvironments, inhibit fibrosis, and modulate immune responses without systemic exposure. It is applicable to both cellular (e.g., cell transplantation) and non-cellular (e.g., wound healing) therapies.

In Type 1 Diabetes, ViCapsys competes with companies developing stem-cell derived islets (e.g., Vertex Pharmaceuticals via ViaCyte acquisition, Sernova), other encapsulation technologies, and immune tolerance therapies. For diabetic foot ulcers, competition includes advanced wound care companies like Organogenesis and Smith & Nephew, as well as other biologic and cell therapy approaches. The anti-adhesion market features established players with physical barrier products.